Literature DB >> 26738412

Hypercoagulabilty, venous thromboembolism, and death in patients with cancer. A Multi-State Model.

Florian Posch, Julia Riedl, Eva-Maria Reitter, Alexandra Kaider, Christoph Zielinski, Ingrid Pabinger, Cihan Ay1.   

Abstract

Venous thromboembolism (VTE) is a frequent complication of malignancy. The aim of this study was to investigate whether multi-state modelling may be a useful quantitative approach to dissect the complex epidemiological relationship between hypercoagulability, VTE, and death in cancer patients. We implemented a three-state/three-transition unidirectional illness-death model of cancer-associated VTE in data of 1,685 cancer patients included in a prospective cohort study, the Vienna Cancer and Thrombosis Study (CATS). During the two-year follow-up period, 145 (8.6 %) patients developed VTE, 79 (54.5 %) died after developing VTE, and 647 (38.4 %) died without developing VTE, respectively. VTE events during follow-up were associated with a three-fold increase in the risk of death (Transition Hazard ratio (HR)=2.98, 95 % confidence interval [CI]: 2.36-3.77, p< 0.001). This observation was independent of cancer stage. VTE events that occurred later during follow-up exerted a stronger impact on the risk of death than VTE events that occurred at earlier time points (HR for VTE occurrence one year after baseline vs at baseline=2.30, 95 % CI: 1.28-4.15, p=0.005). Elevated baseline D-dimer levels emerged as a VTE-independent risk factor for mortality (HR=1.07, 95 % CI: 1.05-1.08, p< 0.001), and also predicted mortality risk in patients who developed VTE. A higher Khorana Score predicted both the risk for VTE and death, but did not predict mortality after cancer-associated VTE. In conclusion, multi-state modeling represents a very potent approach to time-to-VTE cohort data in the cancer population, and should be used for both observational and interventional studies on cancer-associated VTE.

Entities:  

Keywords:  Venous thrombosis; cancer; epidemiological studies

Mesh:

Year:  2016        PMID: 26738412     DOI: 10.1160/TH15-09-0758

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  23 in total

1.  Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.

Authors:  Florian Moik; Wei-Shin Evelyn Chan; Sarah Wiedemann; Christoph Hoeller; Felix Tuchmann; Marie-Bernadette Aretin; Thorsten Fuereder; Sabine Zöchbauer-Müller; Matthias Preusser; Ingrid Pabinger; Cihan Ay
Journal:  Blood       Date:  2021-03-25       Impact factor: 22.113

2.  D-dimer measured at first venous thromboembolism is associated with future risk of cancer.

Authors:  Olga V Gran; Sigrid K Brækkan; Benedikte Paulsen; Hanne Skille; John-Bjarne Hansen
Journal:  Haematologica       Date:  2016-09-09       Impact factor: 9.941

3.  Prevention of Venous Thromboembolism in Pancreatic Cancer: Breaking Down a Complex Clinical Dilemma.

Authors:  Matthew C Dallos; Andrew B Eisenberger; Susan E Bates
Journal:  Oncologist       Date:  2019-10-01

4.  Update from the clinic: what's new in the diagnosis of cancer-associated thrombosis?

Authors:  Erica A Peterson; Agnes Y Y Lee
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 5.  High rates of venous thromboembolic events in patients undergoing systemic therapy for urothelial carcinoma: A systematic review and meta-analysis.

Authors:  Ajay Gopalakrishna; Thomas A Longo; Joseph J Fantony; Uma Doshi; Michael R Harrison; Megan Van Noord; Brant A Inman
Journal:  Urol Oncol       Date:  2016-06-04       Impact factor: 3.498

Review 6.  Prevention of Venous Thromboembolism in Pancreatic Cancer: Breaking Down a Complex Clinical Dilemma.

Authors:  Matthew C Dallos; Andrew B Eisenberger; Susan E Bates
Journal:  Oncologist       Date:  2019-10-01

7.  Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist's impact on anticoagulant therapy.

Authors:  Esin Aysel Kandemir; Aygin Bayraktar-Ekincioglu; Saadettin Kilickap
Journal:  Support Care Cancer       Date:  2020-08-10       Impact factor: 3.603

8.  NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.

Authors:  Katharina T Prochazka; Thomas Melchardt; Florian Posch; Konstantin Schlick; Alexander Deutsch; Christine Beham-Schmid; Lukas Weiss; Thomas Gary; Daniel Neureiter; Eckhard Klieser; Richard Greil; Peter Neumeister; Alexander Egle; Martin Pichler
Journal:  Br J Cancer       Date:  2016-10-20       Impact factor: 7.640

Review 9.  Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis.

Authors:  Umair T Khan; Alex J Walker; Sadaf Baig; Tim R Card; Cliona C Kirwan; Matthew J Grainge
Journal:  BMC Cancer       Date:  2017-11-10       Impact factor: 4.430

10.  Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study.

Authors:  Nick van Es; Marcello Di Nisio; Gabriela Cesarman; Ankie Kleinjan; Hans-Martin Otten; Isabelle Mahé; Ineke T Wilts; Desirée C Twint; Ettore Porreca; Oscar Arrieta; Alain Stépanian; Kirsten Smit; Michele De Tursi; Suzanne M Bleker; Patrick M Bossuyt; Rienk Nieuwland; Pieter W Kamphuisen; Harry R Büller
Journal:  Haematologica       Date:  2017-05-26       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.